 Interim results from Tiziana Life Sciences PLC revealed the significant progress made by the drug developer in the first six months of the year. In six month period to June 30, the group was able to provide the first early demonstration that its monoclonal antibody mAB treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly. 